Hot Flash Clinical Trials

Are you a woman experiencing menopause? If so you may be facing the unpleasant symptoms of hot flashes and night sweats. These are some of the symptoms of menopause that pharmaceutical companies are trying to specifically find treatments for. Horizons Clinical Research Center, LLC often conducts studies for these new ...

Hot flashes are the most frequent symptom of menopause and may be related to changes in circulation. Hot flashes occur when the blood vessels near the skin's surface dilate to cool. They may be accompanied by a red, flushed face; sweating; rapid heart rate; and chills. The severity and duration ...

Currently we have the following studies: Birth Control/ Contraceptive Vaginal Atrophy Pain During Intercourse Dysplasia Endometriosis Pap Smear Mammogram Bone Density Osteoporosis Nocturia Uterine Fibroids Uterine Bleeding Post Menopausal Studies HPV STD Hot Flashes

If so, you may be eligible to participate in a clinical research study to test the safety and effectiveness of an investigational medication, which is taken by mouth, in women who are experiencing moderate to severe vasomotor symptoms, commonly called hot flashes, associated with menopause. Give us a call or ...

Many postmenopausal women have vasomotor symptoms during adjuvant hormonal treatment for breast cancer. PCC-100 is a pollen extract used for alleviation of postmenopausal symptoms. In a randomised, double blinded study pollen extract PCC-100 will be used to treat vasomotor complaints in postmenopausal women under adjuvant hormonal treatment and also in ...

Hot flashes are one of the most common symptoms that are experienced in women during perimenopause, menopause, and as a result of treatment of cancer such as breast cancer. Hot flashes, also known as vasomotor symptoms (VMS) may decrease a woman's quality of life due to discomfort, disruption of daily ...

Women will be recruited from the community through flyers. They will call into a study phone line at which time they will be screened for their initial eligibility using a telephone screener. Women who are eligible and willing to participate, will come to the Research Center in Winston-Salem to be ...

A randomized, double-blinded, placebo-controlled trial of uninterrupted transdermal nitrate therapy in 140 peri- or postmenopausal women who have frequent hot flashes. Women will be randomly assigned to uninterrupted use of transdermal nitrate therapy (participant directed dose-escalation of 0.2 to 0.6 mg/hr) or identical-appearing placebo patches for 12 weeks.

This study will consist of a screening period and a 52 week treatment period. Safety follow up will occur 3 weeks after the last dose of study drug.

This study will consist of a screening period and a 52 week treatment period. Safety follow up will occur 3 weeks after the last dose of study drug.